Summary
The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
Analysis
The approval of Iressa in advanced NSCLC with activating mutations of EGFR-TK will represent another option in the therapeutic strategy of this disease in Europe in a short while. But in the common Medical Oncologists' opinion gefitinib is a lot alike to the other available anti-EGFR TKI. On the basis of technical (analysis of the mutational status), economical (costs of the drug and of the above mentioned procedure) and regulatory (approval of Tarceva in the maintenance setting) aspects we will make our choice...
Rossana Berardi, MD consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
